On March 2, 2021 Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, reported a new research development and licensing agreement (Press release, Oscotec, MAR 2, 2021, View Source [SID1234575874]). Oscotec and Beactica will initially jointly collaborate concerning research and early preclinical development of novel anti-cancer drug candidates arising out of Beactica’s LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica’s programme. Beactica is eligible to receive up to EUR 149 million in potential preclinical, clinical and regulatory milestones, including an upfront and equity payment from Oscotec upon signing of the agreement. Furthermore, Beactica is eligible to receive double-digit royalties on commercial sales of the products resulting from the partnership. Beactica is also entitled to revenue shares from any related future licensing activities by Oscotec. Full financial details remain undisclosed.

"We are thrilled about the opportunity to work with Beactica on the LSD1 allosteric inhibitor programme that we hope opens up very unique and exciting possibilities," said Dr Taeyoung Yoon, CEO/CSO of Oscotec. "Not only could this opportunity fill our need of balancing the preclinical pipeline in the short term, we are convinced that the partnership will also bring to us added value of collaborative science where the two companies complement each other extremely well.""This is a landmark agreement for Beactica, and we are delighted to be working with Oscotec." said Dr Per Källblad, CEO of Beactica Therapeutics. "Their commitment to building a strong clinical pipeline of targeted therapeutics in immunology and oncology makes Oscotec an ideal partner for our programme."

On March 2, 2021 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, reported that members of Transgene’s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences (Press release, Transgene, MAR 2, 2021, View Source [SID1234575873]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4:

Éric Quéméneur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session ‘Where next with Oncolytics’ about Antibody armed oncolytic viruses (ID 42)
Date & Time: March 3rd at 4.20pm (CET)
Royal Society Meeting on ‘Immuno-oncology: How to get the immune system to beat cancer’ which will take place March 24-25:

This Royal Society meeting will explore immuno-oncology therapies – both current and recent technologies. Eric Quéméneur will participate in the immuno-oncology breakthroughs session.
Date & Time: March 24th at 3.50pm (GMT)
4th Annual European Neoantigen Summit which will take place April 20-22:

Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines, will be speaking about TG4050: Viral immunotherapy meets AI technology
Date & Time: April 22nd at 1pm (CET)

On March 1, 2021 Window Therapeutics reported that in March, 2020, the company in conjunction with the Johnson Lab at The Massachusetts Institute of Technology was awarded the prestigious Assay Cascade Grant, for its Window-Bortezomib program for Multiple Myeloma, from the Nanotechnology Characterization Laboratory (NCL), a division of the National Cancer Institute and the Frederick National Laboratory for Cancer Research (Press release, Window Therapeutics, MAR 1, 2021, View Source [SID1234609535]). The NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program.
Nanomedicines accepted into the program undergo a rigorous evaluation ranging from sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are conducted free of charge for Awardees. Initiation of the evaluation of the Window-Bortezomib program began in the first half of 2021 with developmental research currently in progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 1, 2021 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, reported that it will present at the Cowen 41st Annual Health Care Conference being held virtually from March 1-4, 2021 (Press release, Cue Biopharma, MAR 1, 2021, https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-present-cowen-41st-annual-health-care-conference [SID1234608285]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the conference, Cue Biopharma will provide an overview highlighting recent developments of the Immuno-STAT (Selective Targeting and Alteration of T cells) platform, its expanding pipeline and anticipated milestones. The presentation will also include an update on the Company’s ongoing Phase 1 monotherapy dose escalation trial of CUE-101 as well as its combination trial of CUE-101 with KEYTRUDA (pembrolizumab) as first-line treatment for HPV+ recurrent/metastatic head and neck cancer.

Presentation Details

Date and Time: Thursday, March 4, 2021 at 9:10 a.m. EST
Webcast Link: https://wsw.com/webcast/cowen81/cue/1782129
A live and archived webcast of the presentation will be available in the Investors & Media section of the Company’s website at www.cuebiopharma.com. The presentation will be archived for 30 days.

On March 1, 2021 Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of their biosimilar Bevacizumab, co-developed with Viatris, to be marketed as Abevmy (injection bevacizumab 100mg and 400mg) (Press release, Biocon, MAR 1, 2021, View Source [SID1234594757]). Abevmy is a biosimilar to Roche’s Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The decision of the European Commission (EC) is expected in May 2021, which, when approved, will grant marketing authorization in the 27 European Union (EU) member countries and European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. For the U.K., the Medicines and Healthcare Products Regulatory Agency’s "reliance procedure" will be followed, and the U.K. marketing authorization can be expected shortly after the EC decision.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, said: "CHMP’s decision to recommend approval of our biosimilar Bevacizumab brings us a step closer to enable affordable access to this biologic therapy for cancer patients in the EU along with our partner Viatris. It is an outcome of our commitment to expand access for patients leveraging our science and global scale manufacturing for a range of biosimilars. Through bTrastuzumab and bPegfilgrastim we are already making a difference to the lives of cancer patients in several EU countries. We look forward to a final decision from the European Commission approving biosimilar Bevacizumab, which will add to our efforts in cancer care."

Abevmy, bBevacizumab, is a recombinant "humanized" monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and neutralizes its biologic activity. Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth.